CareDx Reports 39% Revenue Growth to $117.7 Million, Achieves Net Income Turnaround

CareDx, Inc. reported significant financial improvements in its latest quarterly filing, with total revenue reaching $117.7 million for the three months ended March 31, 2026, marking a 39% increase from $84.7 million in the same period last year. The company's testing services revenue, which constitutes the majority of its income, surged by 48% to $91.4 million, driven by a 17% increase in testing volume. Additionally, CareDx achieved a net income of $2.8 million, a notable turnaround from a net loss of $10.4 million in the first quarter of 2025.

The company's operational metrics also reflected positive trends, with approximately 54,900 tests performed during the quarter. This increase in testing volume contributed to an average revenue per test of approximately $1,660, which included $14 million in revenue recognized from prior periods. However, product revenue saw a slight decline of 4%, totaling $10.3 million, while patient and digital solutions revenue grew by 33% to $16 million, indicating a diversified revenue stream.

In terms of strategic developments, CareDx announced plans to divest its lab products business to Eurobio Scientific for $170 million in cash, a move aimed at streamlining operations. Additionally, the company entered into an agreement to acquire Naveris, Inc. for $160 million, with potential additional payments based on revenue milestones. These acquisitions and divestitures are part of CareDx's strategy to enhance its core offerings in transplantation and digital health solutions.

The company also reported a decrease in total operating expenses, which rose by 19% to $116.5 million, primarily due to increased costs in sales and marketing, research and development, and general administrative expenses. Notably, litigation settlement expenses decreased significantly, contributing to the overall improvement in net income. As of March 31, 2026, CareDx had cash, cash equivalents, and marketable securities totaling $198.1 million, providing a solid liquidity position to support ongoing operations and strategic initiatives.

Looking ahead, CareDx remains optimistic about its growth trajectory, emphasizing its commitment to expanding its testing services and digital health solutions. The company anticipates that its existing cash balance, along with expected cash flows from operations, will be sufficient to meet its anticipated cash requirements for the next 12 months. CareDx's management continues to focus on enhancing its product offerings and expanding its market presence, particularly in the transplantation sector.